Nanomedical Diagnostics Partners with Rogue Valley Microdevices to Create Breakthrough

Nanomedical Diagnostics "NanoMed", a Serra Capital II portfolio company, has announced its parternship with Rogue Valley Microdevices to create a breakthrough product. By working together, these two companies have found a way to make a product that will study molecules during pharmaceutical experiments. 

NanoMed is the first company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products. 

Source: https://ktvl.com/news/local/rogue-valley-microdevices-partnership-with-nanomedical-diagnostics-creates-breakthrough

New Patent Issued to Nanomedical Diagnostics

Nanomedical Diagnostics, a Serra Capital II portfolio company, announced a new patent issued to the company on Oct 17. The new patent is for the use of graphene biosensors with DNA probes to identify DNA sequences for precision medicine, and will enable the company’s technology to bring the benefits of lower costs, easier process, and higher throughput to the world of liquid biopsy and other DNA detection applications.

Nanomed is a life science company that has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers sensitive real-time direct detection of biomolecules. As the world’s only mass-manufacturer of graphene biosensors, Nanomed’s mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and diagnostic and health monitoring platforms.

Source: http://www.prweb.com/releases/nanomedical_diagnostics/dna_probe_patent_issued/prweb14810978.htm

Nanomedical Diagnostics' Agile R100 Detects Zika

Nanomedical Diagnostics, a Serra Capital II portfolio company, has announced a new publication in Biosensors and Bioelectronics demonstrating detection of Zika viral antigen using their label-free Agile R100 biosensor.  Nano is a cutting-edge life science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development.

The Zika virus, a mosquito-borne infection, has been shown to be a cause of microcephaly and other severe fetal brain defects. For pregnant women, it is especially important to reliably identify Zika virus infection in a timely manner, but current methods show high false positive rates and can take weeks to return test results. The compact and portable Agile R100 represents a potential methodology to identify Zika infection promptly.

Nanomedical Diagnostics Will Present at SLAS 2017

Nanomedical Diagnostics, a Serra Capital II portfolio company, is set to present field effect biosensing for fragment-based drug discovery at the 2017 Society for Laboratory Automation and Screening (SLAS) conference in Washington, D.C. from Feb. 6 to Feb. 8.

Nanomed has developed a breakthrough electronic assay based on Field Effect Biosensing (FEB) technology that provides real-time, label-free kinetic binding and affinity data. 

“Because Field Effect Biosensing measures electrical changes instead of mass, the technology can sense in solutions such as DMSO which cause a high level of background noise on optical sensors. We have detected in 10% DMSO with no effect,” says Nanomedical Diagnostics CEO, Ross Bundy. “This provides an excellent alternate methodology for researchers who struggle to measure in complex solvents that are necessary for their candidate compounds.”

Source: http://www.prweb.com/releases/Nanomedical_Diagnostics/SLAS2017/prweb14007568.htm

Nanomedical Diagnostics Announces Peer Reviewed Publication

Nanomedical Diagnostics, a Serra Capital II portfolio company, made a major announcement on October 11. Nano, the biotech company driving the use of label-free graphene biosensor assays in life science research and diagnostics, announced a publication titled “Large Scale Commercial Fabrication of High Quality Graphene-Based Assays for Biomolecule Detection” in the journal Sensors & Actuators B: Chemical. 

The publication describes the company’s translation of Nobel Prize-winning nanoscience into standard electronics assembly processes to manufacture AGILE R100, a new benchtop assay built on break-through field effect biosensing technology. 

Source: http://www.prweb.com/releases/Nanomedical_Diagnostics/AGILE_R100_Publication/prweb13753527.htm

Nanomedical Diagnostics Highlights Launch of Graphene Biosensor at Graphene World Summit

Nanomedical Diagnostics, a Serra Capital portfolio company, is set to present at the Graphene World Summit on September 19 and 20. Nanomedical Diagnostics is a biotech company based in San Diego, CA, and is the first company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products. 

Dr. Brett Goldsmith, Founder and CTO of Nano, will present a session titled “Graphene: Uniting Biology and Electronics," which will showcase the company's commercialized graphene-based AGILE R100 biosensor.  Dr. Goldsmith shares "Graphene has made it possible to link biology directly with electronics for the first time, bringing an entire world of new capabilities to drug discovery and life science research.”

Source: http://www.prweb.com/releases/Nanomedical_Diagnostics/AGILE_R100_and_Graphene/prweb13686944.htm

Nanomedical Diagnostics Announces Breakthrough Study

Nanomedical Diagnostics, a Serra Capital II portfolio company, has announced a breakthrough study published in the Journal of the American Chemical Society on June 20. Nanomedical Diagnostics is a biotech company developing and commercializing graphene biosensors for use in life science research and diagnostics.

The company's novel AGILE Graphene Biosensor has been found to advance kinase research for the development of therapeutic pharmaceuticals, demonstrating previously unattainable measurements for kinase drug discovery. Dr. Nir Qvit, lead author of the study, said “AGILE performed splendidly, and the data was quantitative and reproducible. The technology is one-of-a-kind.”

Source: http://www.pressreleaserocket.net/nanomedical-diagnostics-novel-agile-graphene-biosensor-advances-kinase-research-for-the-development-of-therapeutic-pharmaceuticals/472296/

Nanomedical Diagnostics Launches New Graphene Biosensor

Nanomedical Diagnostics, a Serra Capital II portfolio company, has launched a new graphene biosensor with unprecedented functionality for small molecule and protein analysis. Nanomedical Diagnostics is a biotech company developing and commercializing bioelectronics for use in research and diagnostics.

Nano has completed its first AGILE biosensor Early Access Development Kit test with a lab at the University of Colorado Anschutz Medical Campus. AGILE (Automatic Graphene Immunolinked Electronic) is the world’s first and only commercially available graphene biosensor. The tests resulted in novel measurements that could not be gathered using traditional methods.

University of Colorado Anschutz professor David Clouthier enthuses “this technology is a game-changer for developmental biologists. It opens the field of proteomics to a discipline that’s previously used just RNA data.”

Source: http://www.prweb.com/releases/2016/02/prwe...

Nanomedical Diagnostics Announces Scientific Advisory Board of Top Scientists and Medical Researchers

Nanomedical Diagnostics, a Serra Capital II portfolio company, announced its scientific advisory board of leading scientists and medical researchers on December 11. Nanomedical Diagnostics is a biotech company developing and commercializing cutting-edge graphene biosensor technology for use in research and diagnostics.

The scientific advisory board provides key strategic input, technical guidance, and research expertise to the company as it prepares AGILE Research, its new graphene biosensor for small molecule and protein analysis, for commercial release early next year.

Nanomedical Diagnostics Announces Raise of $1.6MM in Series A Funding

Nanomedical Diagnostics, a Serra Capital II portfolio company, was featured on news.gnom.es on October 13. Nanomedical Diagnostics is a biotech company developing and commercializing bioelectronics for use in research and diagnostics. The company announced the completion of a Series A financing round of $1.6 million, which was led by Serra Ventures.

Tim Hoerr, CEO of Serra Ventures, was quoted enthusing “This company is applying a very novel and powerful technology to a current hot issue– personalized healthcare. Nanomed has a bold, expansive vision, but the team has built interim products and revenue opportunities on the road to their end goal of putting information in people’s hands to make educated health choices.”

Source: http://news.gnom.es/pr/nanomedical-diagnos...